| Malignant neoplasm of breast
Aromasin vs Herceptin Hylecta
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Aromasin vs Herceptin Hylecta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHerceptin Hylecta has a higher rate of injection site reactions vs Aromasin based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Herceptin Hylecta but not Aromasin, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aromasin
Herceptin Hylecta
At A Glance
Oral
Daily
Aromatase inactivator
SC injection
Every 3 weeks
HER2 antagonist
Indications
- Malignant neoplasm of breast
- Advanced breast cancer
- Malignant neoplasm of breast
Dosing
Malignant neoplasm of breast, Advanced breast cancer 25 mg orally once daily after a meal; increase to 50 mg once daily after a meal when administered with a strong CYP 3A4 inducer.
Malignant neoplasm of breast 600 mg/10,000 units administered subcutaneously over approximately 2-5 minutes once every three weeks; no loading dose required; adjuvant patients treated for 52 weeks or until disease recurrence, metastatic patients treated until disease progression.
Contraindications
- Known hypersensitivity to exemestane or any excipient
—
Adverse Reactions
Most common (>=10%) Hot flushes, fatigue, arthralgia, headache, insomnia, increased sweating
Serious Cardiac ischemic events (myocardial infarction, angina, myocardial ischemia), cardiac failure, clinical fractures
Postmarketing Hypersensitivity, hepatitis including cholestatic hepatitis, paresthesia, tendon disorders including tendon rupture and tendonitis and tenosynovitis, acute generalized exanthematous pustulosis, urticaria, pruritus
Most common (>=10%) Alopecia, nausea, administration-related reactions, neutropenia, diarrhea, asthenia, fatigue, vomiting, myalgia, decreased appetite, stomatitis, arthralgia, headache, rash, constipation, pyrexia, cough, anemia, dyspnea, peripheral sensory neuropathy, leukopenia, mucosal inflammation, hot flush, upper respiratory tract infection
Serious Neutropenia (Grade >=3), febrile neutropenia, leukopenia, left ventricular dysfunction, cardiomyopathy, pulmonary toxicity, hypersensitivity reactions
Postmarketing Administration-related reaction, oligohydramnios, glomerulopathy, immune thrombocytopenia, tumor lysis syndrome
Pharmacology
Aromatase inactivator; exemestane is an irreversible steroidal aromatase inactivator that acts as a false substrate for the aromatase enzyme, binding irreversibly to the active site ('suicide inhibition') and significantly lowering circulating estrogen concentrations in postmenopausal women without affecting adrenal corticosteroid or aldosterone biosynthesis.
Trastuzumab is a humanized IgG1 kappa monoclonal antibody that inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC); hyaluronidase reversibly increases subcutaneous tissue permeability by depolymerizing hyaluronan to enhance systemic absorption of trastuzumab.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aromasin
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Herceptin Hylecta
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Aromasin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Herceptin Hylecta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Aromasin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Herceptin Hylecta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Aromasin Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Bone Metastases
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AromasinView full Aromasin profile
Herceptin HylectaView full Herceptin Hylecta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.